Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak demand. Read more on MRNA stock here.

I maintain my Strong Buy rating Lam Research (LRCX) with a revised price target of $455 per share. LRCX’s Q4 2026 results exceeded expectations, supporting an increased FWD non-GAAP EPS estimate to $9 ...

Here's a 100% collectible guide for locations of all treasure chests and secrets buried in the Antocha Wreck in Assassin's ...

Accurate calibration determines the fidelity of a quantum system; however, a full calibration routine is a time-consuming ...

Major stock indexes pulled back sharply ahead of the Federal Reserve’s decision on interest rates and Big Tech earnings ...